Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Knuth

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
International Journal of Cancer|April 23, 2009
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNgStefan Bauer, Jeannette C Oosterwijk-Wakka, Nicole Adrian, et al.
Cancer Immunity|February 8, 2013
A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapyAnurag Gupta, Natko Nuber, Christoph Esslinger, et al.
Frontiers in Immunology|June 4, 2019
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-VaccineMona O Mohsen, Monique Vogel, Carsten Riether, et al.
Cancer Immunology, Immunotherapy : CII|April 6, 2007
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapyJean-Philippe Theurillat, Ursina Zürrer-Härdi, Zsuzsanna Varga, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 25, 2009
Rational development of high-affinity T-cell receptor-like antibodiesGuillaume Stewart-Jones, Andreas Wadle, Anja Hombach, et al.
International Journal of Cancer|November 29, 2007
Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterpartsJean-Philippe Theurillat, Ursina Zürrer-Härdi, Zsuzsanna Varga, et al.
Cancer Immunity|July 17, 2003
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanomaJonathan Cebon, Elke Jäger, Mark J Shackleton, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 1, 2007
NY-BR-1 is a differentiation antigen of the mammary glandDirk Jäger, Valeriy Filonenko, Ivan Gout, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patientsSenta M Walton, Marco Gerlinger, Olga de la Rosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische OnkologieSalah-Eddin Al-Batran, Joerg Thomas Hartmann, Stephan Probst, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
International Journal of Cancer|April 23, 2009
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNgStefan Bauer, Jeannette C Oosterwijk-Wakka, Nicole Adrian, et al.
Cancer Immunity|February 8, 2013
A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapyAnurag Gupta, Natko Nuber, Christoph Esslinger, et al.
Frontiers in Immunology|June 4, 2019
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-VaccineMona O Mohsen, Monique Vogel, Carsten Riether, et al.
Cancer Immunology, Immunotherapy : CII|April 6, 2007
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapyJean-Philippe Theurillat, Ursina Zürrer-Härdi, Zsuzsanna Varga, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 25, 2009
Rational development of high-affinity T-cell receptor-like antibodiesGuillaume Stewart-Jones, Andreas Wadle, Anja Hombach, et al.
International Journal of Cancer|November 29, 2007
Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterpartsJean-Philippe Theurillat, Ursina Zürrer-Härdi, Zsuzsanna Varga, et al.
Cancer Immunity|July 17, 2003
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanomaJonathan Cebon, Elke Jäger, Mark J Shackleton, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 1, 2007
NY-BR-1 is a differentiation antigen of the mammary glandDirk Jäger, Valeriy Filonenko, Ivan Gout, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patientsSenta M Walton, Marco Gerlinger, Olga de la Rosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische OnkologieSalah-Eddin Al-Batran, Joerg Thomas Hartmann, Stephan Probst, et al.
Pageof 13